Evidence map›Paper›PMID 32916818›Full record

ReviewInternational journal of molecular sciences2020

mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection.

Shuqin Xu, Kunpeng Yang, Rose Li, Lu Zhang

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07053072 (A Prospective，Single Arm Clinicial Trial Evaluating PD-1 mRNA LNP Vaccine for the Treatment of Advanced Primary Hepatocellular Carcinoma Failing Standard Therapy), which is not on this map. Cited by 194 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
194citing papers in PubMed, 2 pooled it
16.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07053072 phase1recruitingnot on this mapstarted 2025, after this paper: background citation

A Prospective，Single Arm Clinicial Trial Evaluating PD-1 mRNA LNP Vaccine for the Treatment of Advanced Primary Hepatocellular Carcinoma Failing Standard Therapy

TypeinterventionalSponsorWest China HospitalRan2025 to 2026Enrolled9ConditionsLiver CancerArmsLow Dose PD-1 mRNA LNP Vaccine, High dose PD-1 mRNA LNP vaccines
3 · Its place in the literature

Who cites it

194 citing papers in PubMed, 2 syntheses or guidelines pooled it, 339 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. AlphaFold3: A Transformer in Life Sciences.Current medicinal chemistry · 2026
    Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

134 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Shuqin XuState Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Science, Fudan University, Shanghai 200438, China.
Kunpeng YangState Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Science, Fudan University, Shanghai 200438, China.
Rose LiM.B.B.S., School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.
Lu ZhangState Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Science, Fudan University, Shanghai 200438, China.
Fudan University · CNPeking University · CNState Key Laboratory of Genetic Engineering

Funding

China's 13th Five Year Programs for the prevention and cure of great infectious diseases 2017ZX10201301-005the National Key R&D Program of China No.2018YFD0500900
6 · The paper itself

Abstract

Messenger ribonucleic acid (mRNA)-based drugs, notably mRNA vaccines, have been widely proven as a promising treatment strategy in immune therapeutics. The extraordinary advantages associated with mRNA vaccines, including their high efficacy, a relatively low severity of side effects, and low attainment costs, have enabled them to become prevalent in pre-clinical and clinical trials against various infectious diseases and cancers. Recent technological advancements have alleviated some issues that hinder mRNA vaccine development, such as low efficiency that exist in both gene translation and in vivo deliveries. mRNA immunogenicity can also be greatly adjusted as a result of upgraded technologies. In this review, we have summarized details regarding the optimization of mRNA vaccines, and the underlying biological mechanisms of this form of vaccines. Applications of mRNA vaccines in some infectious diseases and cancers are introduced. It also includes our prospections for mRNA vaccine applications in diseases caused by bacterial pathogens, such as tuberculosis. At the same time, some suggestions for future mRNA vaccine development about storage methods, safety concerns, and personalized vaccine synthesis can be found in the context.

Indexed as

Vaccines, SyntheticDrug Delivery SystemsImmunogenicity, VaccinemRNA VaccinesRNA, MessengermRNA VaccinesRNA, MessengerVaccines, Syntheticcancer therapeuticsdelivery carriersinfectious diseasesin vitro transcriptionmRNAmRNA vaccineself-adjuvanting property

Identifiers

PMID32916818
PMCPMC7554980
OpenAlexW3083934582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.